Milestone reports FY2022 operating loss of $58.4M; NDA for etripamil on track for Q3 2023

Milestone Pharmaceuticals Inc.

Cash, equivalents, and short-term investments of $64.6M as of Dec 31, 2022; plus $50M from March 2023 private placement expected to fund into mid-2025.
NDA submission for etripamil nasal spray in PSVT expected in Q3 2023; Phase 3 RAPID trial met primary endpoint (64.3% conversion vs 31.2% placebo).
Entered $125M strategic financing with RTW Investments: $50M convertible notes and $75M synthetic royalty commitment post-FDA approval.
Seth H.Z. Fischer appointed to Board of Directors effective March 21, 2023; brings commercial expertise from Johnson & Johnson and Vivus.
Full year 2022 operating loss of $58.4M vs $42.9M in 2021; R&D expense $39.8M, G&A $15.7M, commercial $9.1M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Milestone Pharmaceuticals Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2022.

Period: fourth quarter and fiscal year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 29, 2023, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022, which also provided a clinical and corporate update.

View on SEC.gov

22 earnings releases filed in the last 30 days. Browse all earnings releases →

Milestone Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-038073

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.